Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.92M P/E - EPS this Y 81.20% Ern Qtrly Grth -
Income -42.29M Forward P/E - EPS next Y -19.80% 50D Avg Chg -
Sales - PEG - EPS past 5Y - 200D Avg Chg -3.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -63.00%
Recommedations 1.80 Quick Ratio 5.21 Shares Outstanding 30.34M 52W Low Chg 86.00%
Insider Own 1.89% ROA -30.92% Shares Float 17.44M Beta 1.81
Inst Own 82.75% ROE -130.08% Shares Shorted/Prior 1.13M/1.05M Price 0.02
Gross Margin - Profit Margin - Avg. Volume 1,098,677 Target Price 17.60
Oper. Margin - Earnings Date Nov 11 Volume 2,559,857 Change -4.21%
About SKYE BIOSCIENCE INC

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

SKYE BIOSCIENCE INC News
11/18/24 Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
11/15/24 Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
11/14/24 Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
11/07/24 Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
11/04/24 Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
11/01/24 Skye Bioscience to Announce Third Quarter 2024 Results
10/29/24 Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
10/21/24 Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
09/23/24 Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
09/03/24 Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer
08/26/24 Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
08/23/24 Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/22/24 Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
08/09/24 Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
06:30 AM Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity
05:00 AM Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
07/11/24 Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
07/11/24 Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
07/03/24 Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
07/01/24 Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
SKYE Chatroom

User Image PatientTrader1 Posted - 4 days ago

$SKYE from Glaucoma experts to weight loss specialists…. Please RUN AWAY!!!.. its a SCAM from wherever you look at it…….

User Image NoRiskNoGainEver Posted - 4 days ago

$SKYE here you go guys! Food for thought 😏

User Image MissionaryTrader Posted - 5 days ago

$SKYE as disappointing as the recent price action and volume has been with SKYE, it could be worse. I keep hearing people on this board talking up ALT. 32% of their float is shorted. Meanwhile, SKYE‘s float is only shorted around 8%. I still believe this stock will rocket higher on positive data.

User Image YazzJr Posted - 5 days ago

$SKYE A low volume bleed to death.

User Image slayer70 Posted - 5 days ago

$SKYE If this hits a 1$, I think I'll jump back in and play it Once again as a trade.

User Image aricray Posted - 6 days ago

$SKYE Anything under $5.15 is better than the last executive purchases.

User Image YazzJr Posted - 6 days ago

$SKYE This stock drops no problems on very low volume. Not a good sign for the short term. Might revisit the $3's.

User Image Havana20 Posted - 1 week ago

$SKYE I started buying again!!!

User Image Picklerinthekitchen Posted - 1 week ago

$SKYE ouch ! Being patient for under $2

User Image Polsky Posted - 1 week ago

$SKYE buying back in at $1.5

User Image YazzJr Posted - 1 week ago

$SKYE WTF man???

User Image Ronald_Lamb Posted - 1 week ago

$SKYE $ACHV MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏

User Image Multipliers Posted - 1 week ago

$SKYE https://finance.yahoo.com/news/skye-bioscience-surpasses-50-patient-120000058.html

User Image YazzJr Posted - 1 week ago

$SKYE It wants to push above $6...just needs to gather the strength to do it.

User Image Picklerinthekitchen Posted - 1 week ago

$SKYE https://www.fiercebiotech.com/biotech/altimmune-touts-best-class-lean-mass-results-weight-loss-therapy-quest-outdo-big-time

User Image Rascal7777 Posted - 1 week ago

$SKYE meanwhile at ALT

User Image Picklerinthekitchen Posted - 1 week ago

$SKYE $ALT is the best weight loss Nash winner in the short term.

User Image TKrsponsibility Posted - 1 week ago

$SKYE buy DOGE NOW

User Image JosRyan Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. Low Float only 29M outstanding shares. Any buy-in will make this fly to the moon. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $SKYE $ADVM

User Image YazzJr Posted - 2 weeks ago

$SKYE Nice finish. A little pull back at the end there but tempered down the RSI a bit. So maybe some breathing room to continue up next week.

User Image YazzJr Posted - 2 weeks ago

$SKYE SKYE bucking the trend and maybe finishing strong into the end of the day. If this can get above $6 next stop should be $8ish.

User Image YazzJr Posted - 2 weeks ago

$SKYE The movement on this stock is hilarious. Goes way up, redlines on the RSI and fall back down usually staying up a few cents every day...It's going to be a long climb up...but it's fine..

User Image YazzJr Posted - 2 weeks ago

$SKYE Nice ER and Conference Call. Plenty of cash on hand for them to run for the next two and a half years. No worries about dilution any time soon. The Trials are on schedule with data coming out in the second qtr '25(I am hearing April sometime for that data readout.) This should start moving back up to where it was back in May and June. But the big take away was their hefty cash position to last them for the next 8 qtrs or so.

User Image Multipliers Posted - 2 weeks ago

$SKYE The future looks 🌞 bright. "The United States Court of Appeals for the Ninth District vacated the judgment with respect to an outstanding litigation matter. As a result, the Company will be able to recover the $9 million restriction on its cash related to the appeal bond, which is expected to be released before year-end." "Cash and cash equivalents totaled $76.5 million, including restricted cash of $9.1 million on September 30, 2024. The Company expects its current capital to fund projected operations through Q3 2027."

User Image MissionaryTrader Posted - 2 weeks ago

$SKYE a lot of good information from the conference call today regarding the clinical trials and the long term outlook for nimacimab. The institutional Investors that were present on the call and who also participated in the question and answer period lended to the credibility of SKYE as a solid investment as well. Also, it sounds like the appeals court vacated the cummings lawsuit against Skye which will free up around $9m that was tied up with the bond. Highly recommend listing to the call archived on Skye’s website.

User Image RM_111 Posted - 2 weeks ago

$SKYE

User Image RM_111 Posted - 2 weeks ago

$SKYE

User Image Multipliers Posted - 2 weeks ago

$SKYE Shares New Data Via ObesityWeek 2024 Satellite Presentation This week, following its news release on Monday, Skye Bioscience hosted a subsequent satellite event in conjunction with the ObesityWeek 2024 Conference in San Antonio. At this event Skye provided more detail regarding important new pre-clinical data relating to peripheral vs. central CB1 inhibition and the unique potential role of nimacimab as a truly peripherally-restricted CB1 inhibitor. We highlighted data showing that peripheral CB1 inhibition alone is enough to drive significant weight loss. Targeting central CB1 receptors does not significantly impact weight loss and can cause unwanted neuropsychiatric adverse events. Discover how nimacimab stands out by achieving effective peripheral CB1 inhibition without central exposure, leading to powerful benefits: dose-dependent weight loss, fat mass reduction with lean mass preservation, and improved glycemic control. Watch the full presentation here: https://youtu.be/hqa4y9e3APc

User Image YazzJr Posted - 2 weeks ago

$SKYE Wow, do people really use stops with this stock. The MM's went and grabbed your shares. So dumb.

User Image slayer70 Posted - 2 weeks ago

$SKYE Viking just came out with a pill that has promising results

Analyst Ratings
Scotiabank Sector Outperform Sep 30, 24
Piper Sandler Overweight Sep 20, 24
Cantor Fitzgerald Overweight Sep 20, 24
JMP Securities Market Outperform Sep 10, 24
Cantor Fitzgerald Overweight Sep 9, 24
Cantor Fitzgerald Overweight Sep 6, 24
Cantor Fitzgerald Overweight Aug 27, 24
Craig-Hallum Buy Jul 9, 24
Cantor Fitzgerald Overweight Jul 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DHILLON PUNIT Chief Executive Offi.. Chief Executive Officer Aug 25 Buy 0.02 881,000 17,620 25,683,957 08/31/23